New antimicrobial compounds, their use for the treatment of mammalian infections and a new metabolic mechanism
申请人:Leibniz-institut für Naturstoff-Forschung und Infe Infektionsbiologie E.V. Hans-Knöll Institut (HKI)
公开号:US20200407351A1
公开(公告)日:2020-12-31
The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused by mycobacteria. The invention aims at the generation of a new series of benzothiazinone compounds having the potential to overcome the above mentioned problems. The invention is in a preferred embodiment concerned with compounds of the general formula (I), wherein the substituents R
1
to R
15
have the meanings as provided in claim
1
and depending claims.
Synthesis and selective activity of cholinergic agents with rigid skeletons. II.
Three types of compound, quinuclidine-3-spiro-2'-dioxolane (A), piperidine-4-spiro-2'-dioxolane (B), and piperidine-4-spiro-2'-(4'-oxodioxolane) (C) and their methiodides were synthesized. The cholinomimetic activities of these compounds were examined to investigate the relationship between the activities of these compounds, which have rigid skeletons, and those of known muscarinic agents.